Padsevonil

Padsevonil
Clinical data
Other namesUCB-0942; UCB0942; UCB1415943-000
Routes of
administration		Oral
Drug classSynaptic vesicle glycoprotein 2A (SV2A) ligand
Identifiers
  • (4R)-4-(2-chloro-2,2-difluoroethyl)-1-[[2-(methoxymethyl)-6-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]methyl]pyrrolidin-2-one
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC14H14ClF5N4O2S
Molar mass432.79 g·mol−1
3D model (JSmol)
  • COCC1=NN2C(=C(N=C2S1)C(F)(F)F)CN3C[C@H](CC3=O)CC(F)(F)Cl
  • InChI=1S/C14H14ClF5N4O2S/c1-26-6-9-22-24-8(11(14(18,19)20)21-12(24)27-9)5-23-4-7(2-10(23)25)3-13(15,16)17/h7H,2-6H2,1H3/t7-/m1/s1
  • Key:DCXFIOLWWRXEQH-SSDOTTSWSA-N

Padsevonil (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name, JANTooltip Japanese Accepted Name; developmental code name UCB-0942) is a synaptic vesicle glycoprotein 2A (SV2A) ligand which is under development for the treatment of epilepsy. It is much more potent than earlier SV2A ligands like levetiracetam and brivaracetam. However, in contrast to its predecessors, padsevonil's chemical structure has been modified such that it is no longer a racetam. In addition, padsevonil also interacts with synaptic vesicle glycoprotein 2B (SV2B) and 2C (SV2C). The drug is being developed by UCB. As of November 2023, it is in phase 2 clinical trials.

References

  1. 1 2 3 4 "Padsevonil". AdisInsight. 5 November 2023. Retrieved 26 February 2025.
  2. 1 2 3 4 5 Wu PP, Cao BR, Tian FY, Gao ZB (May 2024). "Development of SV2A Ligands for Epilepsy Treatment: A Review of Levetiracetam, Brivaracetam, and Padsevonil". Neuroscience Bulletin. 40 (5): 594–608. doi:10.1007/s12264-023-01138-2. PMC 11127901. PMID 37897555.
  3. 1 2 3 "Delving into the Latest Updates on Padsevonil with Synapse". Synapse. 8 February 2025. Retrieved 26 February 2025.